Evidence map›Paper›PMID 33222607›Full record

ArticleCell cycle (Georgetown, Tex.)2020

microRNA-877 contributes to decreased non-small cell lung cancer cell growth via the PI3K/AKT pathway by targeting tartrate resistant acid phosphatase 5 activity.

Xue Bai, Changjun He, Bicheng Fu, Xianglong Kong, Jianlong Bu, Kaibin Zhu, Wei Zheng, Fucheng Zhou, Boxiong Ni

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. RUNX1 promotes NSCLC progression by ACP5/SMAD3-mediated M2 macrophage polarization.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue Bai
Changjun He
Bicheng Fu
Xianglong Kong
Jianlong Bu
Kaibin Zhu
Wei Zheng
Fucheng Zhou
Boxiong Ni

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of cancer death in both men and women. microRNAs (miRs) can exert important functions in cancer development. However, the role of miR-877 in NSCLC as it relates to tartrate resistant acid phosphatase 5 (ACP5) is unknown. For this study, the gain-and-loss-of-function experiments were performed to explore the effects of miR-877 and ACP5 on NSCLC. miR-877 expression in LC and paracancerous tissues, lung epithelial cell line and NSCLC cell lines was detected, and the association between miR-877 expression and clinical features of LC patients was analyzed. The levels of ACP5, epithelial-mesenchymal transition (EMT) markers and apoptosis-related proteins were measured.

Indexed as

A549 CellsAgedAnimalsCarcinoma, Non-Small-Cell LungFemaleGrowth InhibitorsHumansMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsMiddle AgedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTartrate-Resistant Acid PhosphataseACP5 protein, humanGrowth InhibitorsMicroRNAsMIRN877 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTartrate-Resistant Acid PhosphatasemicroRNA-877Non-small cell lung cancerPI3K/AKT pathwaytartrate resistant acid phosphatase 5

Identifiers

PMID33222607
PMCPMC7751652
OpenAlexW3110098790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.